Holen Sie sich die Stockscreener-App
185.78
0.68%
1.1085
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$184.67
Offen:
$189.29
24-Stunden-Volumen:
99,755
Relative Volume:
0.49
Marktkapitalisierung:
$3.66B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
74.02
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
-4.70%
1M Leistung:
-8.17%
6M Leistung:
+69.83%
1J Leistung:
+59.82%
1-Tages-Spanne:
$185.80
$192.44
1-Wochen-Bereich:
$183.23
$197.00
52-Wochen-Spanne:
$93.58
$212.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
185.93 | 3.63B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Citigroup Initiates Coverage On LGND with a Buy Rating | LGND St - GuruFocus
Major Decision: Jason Aryeh Exercises Options, Realizing $234K At Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals Stock (LGND) Opinions on 2025 Investor Day and 2026 Guidance - Quiver Quantitative
Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2026 - marketscreener.com
Ligand (LGND) Highlights Strategic Advances and Growth Prospects at Investor Day - GuruFocus
(LGND) Ligand Pharmaceuticals Expects Full Year 2025 Core Revenue Range $225M to $235M - marketscreener.com
(LGND) Ligand Pharmaceuticals Expects Full Year 2026 Revenue Range $245M to $285M, vs. FactSet Est of $259.2M - marketscreener.com
Ligand Pharmaceuticals Provides 2026 Revenue Guidance of $245 Million to $285 Million with Increased Royalty Revenue Outlook - Quiver Quantitative
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance - Yahoo Finance
Is Ligand Pharmaceuticals Incorporated LGDN a good long term investmentGlobal Trade Effects & Demo Trading Rooms Open Daily - earlytimes.in
Ligand Pharmaceuticals IncorporatedEquity Right (LGNXZ) Price Target Increased by 25.41% to 0.00 - Nasdaq
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $91,457.28 in Stock - MarketBeat
Why analysts upgrade Ligand Pharmaceuticals Incorporated stockJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - Newser
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3% - GlobeNewswire Inc.
Can Ligand Pharmaceuticals Incorporated stock double in next 5 yearsInsider Selling & Weekly Chart Analysis and Guides - Newser
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
A Look Into Ligand Pharmaceuticals Inc's Price Over Earnings - Benzinga
Ligand Pharmaceuticals Incorporated $LGND Stake Decreased by Prudential Financial Inc. - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Granite Investment Partners LLC - MarketBeat
Will Ligand Pharmaceuticals Incorporated (LGDN) stock hit analyst forecastsWeekly Market Outlook & Stock Portfolio Risk Control - Newser
Will Ligand Pharmaceuticals Incorporated stock benefit from sector rotationTreasury Yields & Real-Time Volume Triggers - Newser
Ligand Pharmaceuticals Incorporated $LGND Shares Purchased by Russell Investments Group Ltd. - MarketBeat
Is Ligand Pharmaceuticals Incorporated (LGDN) stock at risk of policy regulationBreakout Watch & AI Based Buy/Sell Signal Reports - Newser
How strong is Ligand Pharmaceuticals Incorporated (LGDN) stock earnings growth - Newser
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals (LGND) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Legal & General Group Plc - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Loomis Sayles & Co. L P - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by SG Americas Securities LLC - MarketBeat
Advantage Alpha Capital Partners LP Purchases New Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Portfolio Recap: Why Ligand Pharmaceuticals Incorporated stock could outperform in 2025 - BỘ NỘI VỤ
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Peering Into Ligand Pharmaceuticals Inc's Recent Short Interest - Benzinga
Will Ligand Pharmaceuticals Incorporated stock deliver better than expected guidance2025 Volatility Report & Reliable Volume Spike Trade Alerts - BỘ NỘI VỤ
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know - AOL.com
Ligand Pharmaceuticals Incorporated $LGND Stake Boosted by Geode Capital Management LLC - MarketBeat
Ligand Pharma stock maintains Outperform rating at RBC ahead of Investor Day By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says - marketscreener.com
Is Ligand Pharmaceuticals Incorporated (LGDN) stock testing key supportPortfolio Return Report & Stepwise Swing Trade Plans - newser.com
Ligand Pharmaceuticals (LGND) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Will Ligand Pharmaceuticals Incorporated stock attract ESG investorsJuly 2025 Closing Moves & Low Risk Investment Opportunities - newser.com
Is Ligand Pharmaceuticals Incorporated stock positioned for long term growth2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Why Ligand Pharmaceuticals Incorporated (LGDN) stock is favored by hedge fundsPortfolio Gains Report & Real-Time Sentiment Analysis - newser.com
Ligand Pharmaceuticals (LGND): Assessing Valuation After Strong Recent Share Price Gains - Yahoo Finance
Is Ligand Pharmaceuticals Incorporated (LGDN) stock good for long term investingCPI Data & Weekly Setup with High ROI Potential - newser.com
Will Ligand Pharmaceuticals Incorporated (LGDN) stock outperform foreign stocks2025 Fundamental Recap & Daily Technical Forecast Reports - newser.com
How Ligand Pharmaceuticals’ Strong Q3 Results and Raised Guidance May Impact LGND Investors - Yahoo Finance
Intraday pattern recognizer results for Ligand Pharmaceuticals Incorporated - newser.com
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? - Yahoo Finance UK
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):